Literature DB >> 29924959

Immunohistochemical expression of NEDD9, E-cadherin and γ-catenin and their prognostic significance in pancreatic ductal adenocarcinoma (PDAC).

Petra Radulović1, Božo Krušlin.   

Abstract

Extensive research is being conducted to identify novel diagnostic, predictive and prognostic biomarkers for pancreatic ductal adenocarcinoma (PDAC), as only a few markers have been routinely used so far with limited success. Our aim was to assess the expression of neural precursor cell expressed developmentally down-regulated protein 9 (NEDD9), E-cadherin, and γ-catenin in PDAC in relation to clinicopathological parameters and patient survival. We also investigated if there is a correlation of NEDD9 expression with E-cadherin or γ-catenin. The protein expression was determined by immunohistochemistry in 61 PDAC and 61 samples of normal pancreatic tissue. The log rank test and Kaplan-Meier survival curve were used for survival analysis. E-cadherin and γ-catenin expressions were reduced in PDAC, and completely retained in normal pancreatic tissue. Expression of NEDD9 was significantly increased in PDAC (strong expression in 78.7% of cases and moderate in 21.3%) and reduced in normal pancreatic tissue (strong positivity in 45.9% of cases, moderate in 31.1%, and weak in 23%). There was a positive correlation between reduced E-cadherin and γ-catenin expression in PDAC (p = 0.015). The loss or reduced expression of E-cadherin had a negative impact on patient survival (p = 0.020). A negative correlation between E-cadherin expression and tumor grade was also observed (p = 0.011). Decreased E-cadherin expression was more common in male patients with PDAC (81.3% vs. 60% for females, p = 0.005). γ-catenin and NEDD9 expressions were not statistically correlated with tumor stage and grade, gender, nor with patient survival. Our results support the role of NEDD9, E-cadherin and γ-catenin proteins in PDAC, but further research should clarify in detail their mechanism of action in pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29924959      PMCID: PMC6087551          DOI: 10.17305/bjbms.2018.2378

Source DB:  PubMed          Journal:  Bosn J Basic Med Sci        ISSN: 1512-8601            Impact factor:   3.363


  28 in total

1.  Plakoglobin regulates cell motility through Rho- and fibronectin-dependent Src signaling.

Authors:  Viktor Todorović; Bhushan V Desai; Melanie J Schroeder Patterson; Evangeline V Amargo; Adi D Dubash; Taofei Yin; Jonathan C R Jones; Kathleen J Green
Journal:  J Cell Sci       Date:  2010-09-28       Impact factor: 5.285

2.  Analysis of E-, N-cadherin, alpha-, beta-, and gamma-catenin expression in human pancreatic carcinoma cell lines.

Authors:  Eiji Toyoda; Ryuichiro Doi; Masayuki Koizumi; Kazuhiro Kami; Daisuke Ito; Tomohiko Mori; Koji Fujimoto; Sanae Nakajima; Michihiko Wada; Masayuki Imamura
Journal:  Pancreas       Date:  2005-03       Impact factor: 3.327

3.  Plakoglobin suppresses keratinocyte motility through both cell-cell adhesion-dependent and -independent mechanisms.

Authors:  Taofei Yin; Spiro Getsios; Reto Caldelari; Andrew P Kowalczyk; Eliane J Müller; Jonathan C R Jones; Kathleen J Green
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-01       Impact factor: 11.205

4.  Loss of E-cadherin and beta-catenin is correlated with poor prognosis of ampullary neoplasms.

Authors:  Hui-Ping Hsu; Yan-Shen Shan; Ying-Tai Jin; Ming-Derg Lai; Pin-Wen Lin
Journal:  J Surg Oncol       Date:  2010-04-01       Impact factor: 3.454

Review 5.  Preclinical and clinical studies of the NEDD9 scaffold protein in cancer and other diseases.

Authors:  Elena Shagisultanova; Anna V Gaponova; Rashid Gabbasov; Emmanuelle Nicolas; Erica A Golemis
Journal:  Gene       Date:  2015-05-09       Impact factor: 3.688

6.  Knock-down of plasminogen-activator inhibitor-1 enhances expression of E-cadherin and promotes epithelial differentiation of human pancreatic adenocarcinoma cells.

Authors:  Monica Lupu-Meiri; Elizabeth Geras-Raaka; Ruth Lupu; Hagit Shapira; Judith Sandbank; Liora Segal; Marvin C Gershengorn; Yoram Oron
Journal:  J Cell Physiol       Date:  2012-11       Impact factor: 6.384

7.  Expression of NEDD9 in pancreatic ductal adenocarcinoma and its clinical significance.

Authors:  Yu-Zheng Xue; Ying-Yue Sheng; Zong-Liang Liu; Zhe-Qiang Wei; Hai-Yan Cao; Yan-Min Wu; Yu-Feng Lu; Li-Hua Yu; Jian-Ping Li; Zhao-Shen Li
Journal:  Tumour Biol       Date:  2012-12-18

Review 8.  Epidemiology of pancreatic cancer: an overview.

Authors:  Sara Raimondi; Patrick Maisonneuve; Albert B Lowenfels
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-10-06       Impact factor: 46.802

Review 9.  Src-mediated regulation of E-cadherin and EMT in pancreatic cancer.

Authors:  Nagaraj S Nagathihalli; Nipun B Merchant
Journal:  Front Biosci (Landmark Ed)       Date:  2012-06-01

10.  Loss of E-cadherin expression and outcome among patients with resectable pancreatic adenocarcinomas.

Authors:  Seung-Mo Hong; Ang Li; Kelly Olino; Christopher L Wolfgang; Joseph M Herman; Richard D Schulick; Christine Iacobuzio-Donahue; Ralph H Hruban; Michael Goggins
Journal:  Mod Pathol       Date:  2011-05-06       Impact factor: 7.842

View more
  6 in total

1.  POSITIVE EXPRESSION OF NEDD9 IN HEAD AND NECK CANCER IS RELATED TO BETTER SURVIVAL PERIOD.

Authors:  Iva Ledinsky Opačić; Krešimir Gršić; Sanda Šitić; Ivan Penavić; Marija Pastorčić Grgić; Božena Šarčević
Journal:  Acta Clin Croat       Date:  2019-12       Impact factor: 0.780

2.  Clinical Significance of Serum NEDD9 Levels in Patients with Pancreatic Cancer.

Authors:  Cigdem Usul Afsar; Mehmet Karabulut; Senem Karabulut; Safiye Tokgoz Ozal; Murat Cikot; Murat Serilmez; Faruk Tas
Journal:  Biomolecules       Date:  2018-12-10

3.  Prognostic and Clinicopathological Significance of E-Cadherin in Pancreatic Cancer Patients: A Meta-Analysis.

Authors:  Pengbo Wang; Zengkuan Zhu
Journal:  Front Oncol       Date:  2021-04-12       Impact factor: 6.244

4.  Overexpression of Circular RNA circ_0013587 Reverses Erlotinib Resistance in Pancreatic Cancer Cells Through Regulating the miR-1227/E-Cadherin Pathway.

Authors:  Huiting Xu; Runzhi Chen; Qian Shen; Dongmei Yang; Hui Peng; Jin Tong; Qiang Fu
Journal:  Front Oncol       Date:  2021-09-06       Impact factor: 6.244

5.  Expression of NEDD9 and connexin-43 in neoplastic and stromal cells of gastric adenocarcinoma.

Authors:  Ivan Lerotić; Petra Vuković; Davor Hrabar; Zvonimir Misir; Ivan Kruljac; Tajana Pavić; Jelena Forgač; Petra Ćaćić; Monika Ulamec
Journal:  Bosn J Basic Med Sci       Date:  2021-10-01       Impact factor: 3.363

6.  MicroRNA-1252-5p, regulated by Myb, inhibits invasion and epithelial-mesenchymal transition of pancreatic cancer cells by targeting NEDD9.

Authors:  Yuzheng Xue; Tielong Wu; Yingyue Sheng; Yao Zhong; Benshun Hu; Chuanqing Bao
Journal:  Aging (Albany NY)       Date:  2021-07-27       Impact factor: 5.682

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.